{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-226747","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2026-05-15T20:13:11+00:00","discovered_at":"2026-05-15T20:19:00.265641+00:00","generated_at":"2026-05-15T20:19:47.775679+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation","bullets":["Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.","Net loss $6.9M ($1.05 per share) vs $17.4M in Q1 2025 (post reverse split).","Revenue $1.0M from CPRIT grant and CNSide billings; operating loss $7.1M vs $3.5M year ago.","FDA granted Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas and ependymoma.","CNSide expanded payer coverage to ~81M lives including Blue Shield of California; unique PLA code secured."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-226747","json":"https://secwatch.observer/filing/0001193125-26-226747.json","markdown":"https://secwatch.observer/filing/0001193125-26-226747.md","text":"https://secwatch.observer/filing/0001193125-26-226747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/0001193125-26-226747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/pstv-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:19:47.775679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a85dd89cb1f5acd597538c473a4fb753d9118b01","claim":"PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $1.0 million, net income $6.9 million, or $1.05 per basic share, EPS $1.05 per basic share. Guidance reaffirmed.","evidence_excerpt":"2026 public offering, partially offset by operating expenditures during the quarter and paydown of the investor liability at December 31, 2025 of $4.5 million • Recognized $1.0 million in revenue in the first quarter of 2026, including grant revenue from CPRIT for the advancement of REYOBIQ in LM and CNSide diagnostic billings, compared to $1.1 million in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/0001193125-26-226747-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$1.0 million"},{"label":"Net income","value":"$6.9 million, or $1.05 per basic share"},{"label":"EPS","value":"$1.05 per basic share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}